Voyager Therapeutics is a biotechnology company focused on developing innovative gene therapies for neurological diseases
The company utilizes its proprietary adeno-associated viral (AAV) platform to create targeted treatments aimed at addressing disorders such as Parkinson's disease, Huntington's disease, and other neurodegenerative conditions. By leveraging advancements in gene delivery techniques, Voyager Therapeutics aims to provide long-lasting solutions that potentially improve the quality of life for patients suffering from these debilitating illnesses. Their commitment to scientific research and clinical development centers around delivering transformative therapies to address significant unmet medical needs in neurology.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQVYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQVYGR) for violations of the securities laws.
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The pandemic is predicted to have a long and short term impact on the individual’s mental illness, given the hurdles faced during the crisis, such […]
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Voyager Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.
